Literature DB >> 8522459

Antibacterial properties of AM-1155, a new 8-methoxy quinolone.

M Hosaka1, S Kinoshita, A Toyama, M Otsuki, T Nishino.   

Abstract

AM-1155 is a new 8-methoxy quinolonecarboxylic acid with a broad spectrum of antibacterial activity. It inhibited more than 90% of clinical isolates of methicillin-susceptible Staphylococcus aureus, streptococci, Enterococcus faecalis, most of the Enterobacteriaceae, Acinetobacter calcoaceticus and Haemophilus influenzae at the concentration of 0.39 mg/L. AM-1155 was 2- to 16-fold more active than ciprofloxacin against Gram-positive organisms including methicillin-resistant staphylococci. The antibacterial activity of AM-1155 was almost equal to that of sparfloxacin against a wide range of Gram-positive and Gram-negative species. AM-1155 also showed a good activity against anaerobes. The protective efficacy of AM-1155 against experimental systemic infections with Gram-positive and Gram-negative pathogens in mice was almost equal or superior to that of sparfloxacin. AM-1155 was 5- to 28-times more effective than ciprofloxacin, in terms of ED50 at one week, in staphylococcal and streptococcal infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522459     DOI: 10.1093/jac/36.2.293

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Efficacy of gatifloxacin in experimental Escherichia coli meningitis.

Authors:  I Lutsar; I R Friedland; H S Jafri; L Wubbel; W Ng; F Ghaffar; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 6.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1999       Impact factor: 9.546

8.  Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

9.  Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.

Authors:  E J Goldstein; D M Citron; C V Merriam; K Tyrrell; Y Warren
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

10.  Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Authors:  H Fukuda; S Hori; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.